Shots:
- Shionogi to receive an up front, milestones as well as royalties on sales of the therapy. BioAge to get exclusive US and EU rights to develop and commercialize BGE-17 for COVID-19
- Additionally, BioAge gets an exclusive right to negotiate a license for additional indications and plans to initiate P-II study of BGE-175 for COVID-19 in the H1’21
- BGE-175 is a DP1 receptor antagonist, developed for allergic rhinitis. The results of multiple non-clinical/ clinical trials in 2,400+ subjects & have shown that BGE-175 has high affinity and selectivity to the DP1 receptor1 & is well tolerated & safe
Click here to read full press release/ article | Ref: Shionogi | Image: BusinessWire
The post Shionogi Concludes a License Agreement with BioAge for BGE-175 to Control the Aggravation of COVID-19 first appeared on PharmaShots.
